Professional Documents
Culture Documents
Shieka Report
Shieka Report
• Genetics:
• A family history of MVP increases the risk of developing the condition.
• Structural Changes:
• Age-related degeneration or damage to the valve's collagen can lead to its improper functioning.
• Hormonal Influences:
• Hormones, particularly estrogen, might affect connective tissue strength and contribute to MVP
development.
Some other risk factors for MVP development include:
Graves’ Disease
Ebstein Anomaly
Muscular Dystrophy
Ehlers-Danlos Syndrome
Scoliosis
Advanced medical research undertaken has been able to conclude that the abnormality in the formation of the mitral
valve or its restructuring leads to this condition. This structural difference can be a result of various factors. Though,
the root cause of these factors is still not known. However, they are expected to be closely connected to human
genetics due to disease prevalence in family lines.
Side Effects
and
Management
• While many individuals with MVP remain asymptomatic, others
may experience the following side effects:
• Mitral Regurgitation: The bulging valve may not close properly, leading to blood
flowing backward into the atrium.
• Arrhythmias: Irregular heart rhythms, such as palpitations or atrial fibrillation, might
occur.
• Chest Pain: MVP can cause chest discomfort due to changes in blood flow.
• Endocarditis: The valve's abnormal structure can increase the risk of bacterial
infection.
• Stroke: Blood clots may form due to disrupted blood flow, potentially leading to
stroke.
• Management involves a combination of lifestyle changes, medications,
and in severe cases, surgery:
• Lifestyle: Regular exercise, maintaining a healthy weight, and reducing stress can help
manage symptoms.
• Medications: Beta-blockers or calcium channel blockers can help regulate heart rate and
reduce palpitations.
• Anticoagulants: In cases of blood clot risk, blood thinners might be prescribed.
• Surgery: Surgical intervention might be necessary for severe regurgitation or valve repair.
Treatment For Mitral Valve Prolapse
It may not be necessary for all people suffering from MVP to
undergo treatments as long as it does not result in the
mentioned observable symptoms. The requirement for any MVP
treatment, however, depends on the discretion of the consulting
medical specialist. The Mitral Valve treatment to be followed in
such cases can be the following.
Smith, J., et al. (2020). Long-term Outcomes of Mitral Valve Prolapse. Journal of Cardiology,
10(2), 145-150.
Garcia, R., et al. (2021). Genetic and Molecular Insights into Mitral Valve Prolapse. Circulation
Research, 117(6), 586-597.
https://www.slideshare.net/DinaMostafa1/mitral-valve-prolapse-233171527
https://www.metropolisindia.com/blog/preventive-healthcare/mitral-valve-prolapse/